Crossmark

Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective

Crossref DOI link: https://doi.org/10.1186/s12962-018-0101-3

Published Online: 2018-05-10

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Shah, Dhvani

Driessen, Maurice

Risebrough, Nancy

Baker, Timothy

Naya, Ian

Briggs, Andrew

Ismaila, Afisi S. https://orcid.org/0000-0002-2876-8308
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct02207829 at ClinicalTrials.gov

Documents that mention this clinical trial

Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective
https://doi.org/10.1186/s12962-018-0101-3

nct02236611 at ClinicalTrials.gov

Documents that mention this clinical trial

Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective
https://doi.org/10.1186/s12962-018-0101-3
Funding

Funding for this research was provided by:

GSK
License Information

Text and Data Mining valid from 2018-05-10

Version of Record valid from 2018-05-10
More Information

Article History

Received: 5 December 2017

Accepted: 26 April 2018

First Online: 10 May 2018

Document is current

Any future updates will be listed below